Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 2/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109097 | 1.00 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL4428770 | 1.00 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL21029706 | 0.82 | GABRR1 (0.31) | GABRR1PLGPLATLMNA | |
| SCHEMBL13631051 | 0.82 | GABRR1 (0.31) | GABRR1PLGPLATLMNA | |
| SCHEMBL3581962 | 0.81 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL5260434 | 0.81 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL3953001 | 0.81 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL3953002 | 0.81 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL3581424 | 0.81 | GABRR1 (0.50) | GABRR1PLGPLATLMNAACE | |
| SCHEMBL6567963 | 0.80 | GABRR1 (0.48) | GABRR1PLGPLATLMNAABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| EP-3395814-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20210347756-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2021-11-11 | — | — | US | disclosed |
| US-10875837-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200109127-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2020-04-09 | — | — | US | disclosed |
| US-10221154-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-03-05 | — | — | US | disclosed |
| EP-3395814-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | Blueprint Medicines Corporation (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017182828-A1 | ANTIMICROBIAL AGENTS | THE UNIVERSITY OF WARWICK (GB) | 2017-10-26 | — | — | WO | disclosed |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-06-22 | — | — | US | disclosed |
| US-9434700-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION | 2016-09-06 | — | — | US | disclosed |
| EP-3060560-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | Blueprint Medicines Corporation (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061572-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-04-30 | — | — | US | disclosed |
| US-20090275581-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090264428-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109127-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | GABRR1 1691/4885PLG 1144/4885PLAT 583/4885 |
| US-20090275581-A1 | RENIN INHIBITORS | REN, ACE, SERPINB1 | GABRR1 957/4885PLG 93/4885PLAT 178/4885 |
| US-20210347756-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | GABRR1 1691/4885PLG 1144/4885PLAT 583/4885 |
| US-20170174652-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | GABRR1 1691/4885PLG 1144/4885PLAT 583/4885 |
| US-10875837-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | GABRR1 1691/4885PLG 1144/4885PLAT 583/4885 |
| US-20090264428-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | GABRR1 1416/4885PLG 105/4885PLAT 256/4885 |
| US-20150119405-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | GABRR1 1691/4885PLG 1144/4885PLAT 583/4885 |
| US-10221154-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | GABRR1 1691/4885PLG 1144/4885PLAT 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.